• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

    5/8/24 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email

    LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024.

    "Keros remained focused on clinical execution and continued to make strong progress across our pipeline in the first quarter of 2024," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "We look forward to upcoming milestones in the second quarter of 2024, including providing an update on our ongoing TROPOS Phase 2 clinical trial evaluating KER-012 in patients with pulmonary arterial hypertension ("PAH")."

    Recent Program Updates

    • KER-050 (elritercept) for the treatment of ineffective hematopoiesis to address cytopenias
      • Keros has engaged with the U.S. Food and Drug Administration regarding the design of the planned Phase 3 clinical trial of KER-050 in patients with myelodysplastic syndromes ("MDS"), and expect to provide an update on the planned trial design in mid-2024.
    • KER-012 (cibotercept) for the treatment of PAH and for the treatment of cardiovascular disorders
      • Keros will present a poster abstract from its KER-012 program at the American Thoracic Society ("ATS") 2024 International Conference, to be held from May 17 through May 22, 2024 in San Diego, California. The following abstract was posted to the ATS website on March 19, 2024:
        • Preclinical Presentation: "RKER-012, A Novel Modified ActRIIB Ligand Trap, Reduced Pulmonary Vascular Pathology in a Rat Model of Pulmonary Arterial Hypertension Through Attenuation of TGF-ß Family Autocrine/Paracrine Signaling Within the Vasculature"
          • Session Name: Gaslamp Quarter: Shedding Light on Vascular Pathogenic Mechanisms in PAH
          • Date and Presentation Time: May 21, 2024; 9:15 a.m. – 11:15 a.m. Pacific time

    First Quarter 2024 Financial Results

    Keros reported a net loss of $43.1 million in the first quarter of 2024 as compared to a net loss of $35.8 million in the first quarter of 2023. The increase of $7.3 million for the first quarter was largely due to increased research and development efforts as well as additional investments to support the achievement of Keros' clinical and corporate goals.

    Research and development expenses were $38.3 million for the first quarter of 2024 as compared to $31.1 million for the same period in 2023. The increase of $7.2 million was primarily due to additional research and development efforts, manufacturing activities and personnel expenses to support the advancement of Keros' pipeline.

    General and administrative expenses were $10.3 million for the first quarter of 2024 as compared to $7.8 million for the same period in 2023. The increase of $2.5 million was primarily due to increase in personnel expenses and other external expenses to support Keros' organizational growth.

    Keros' cash and cash equivalents as of March 31, 2024 was $442.4 million compared to $331.1 million as of December 31, 2023. Keros expects that the cash and cash equivalents it had on hand at March 31, 2024 will enable Keros to fund its operating expenses and capital expenditure requirements into 2027.

    About Keros Therapeutics, Inc.

    Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, KER-050 (elritercept), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with myelofibrosis. Keros' second product candidate, KER-012 (cibotercept), is being developed for the treatment of PAH and for the treatment of cardiovascular disorders. Keros' third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.

    Cautionary Note Regarding Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "enable," "expects," "look forward," "plans," "progress" and "will" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros' expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for KER-050 and KER-012, including its regulatory plans; and Keros' expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros' limited operating history and historical losses; Keros' ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros' dependence on the success of its product candidates, KER-050, KER-012 and KER-065; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros' ability to obtain, maintain and protect its intellectual property; and Keros' dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

    These and other risks are described more fully in Keros' filings with the Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K, filed with the SEC on February 28, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investor Contact:

    Justin Frantz

    [email protected] 

    617-221-6042

    KEROS THERAPEUTICS, INC.

    Condensed Consolidated Statements of Operations

    (In thousands, except share and per share data)

    (Unaudited)

     THREE MONTHS ENDED MARCH 31,
     2024   2023 
    REVENUE:   
    Service and other revenue 83   — 
    Total revenue 83   — 
    OPERATING EXPENSES:   
    Research and development (38,258)  (31,091)
    General and administrative (10,308)  (7,778)
    Total operating expenses (48,566)  (38,869)
    LOSS FROM OPERATIONS (48,483)  (38,869)
    OTHER INCOME (EXPENSE), NET   
    Dividend income 5,806   3,105 
    Other expense, net (437)  (40)
    Total other income, net 5,369   3,065 
    Net loss$(43,114) $(35,804)
    Net loss attributable to common stockholders—basic and diluted$(43,114) $(35,804)
    Net loss per share attributable to common stockholders—basic and diluted$(1.21) $(1.26)
    Weighted-average common stock outstanding—basic and diluted 35,685,422   28,369,453 



    KEROS THERAPEUTICS, INC.

    Condensed Consolidated Balance Sheets

    (In thousands, except share and per share data)

    (Unaudited)

     MARCH 31,

    2024
     DECEMBER 31,

    2023
    ASSETS   
    CURRENT ASSETS:   
    Cash and cash equivalents442,443  331,147 
    Accounts receivable226  143 
    Prepaid expenses and other current assets20,457  16,003 
    Total current assets463,126  347,293 
    Operating lease right-of-use assets14,995  15,334 
    Property and equipment, net4,434  4,134 
    Restricted cash1,212  1,212 
    Other long-term assets2,052  2,052 
    TOTAL ASSETS485,819  370,025 
    LIABILITIES AND STOCKHOLDERS' EQUITY    
    CURRENT LIABILITIES:   
    Accounts payable4,986  5,450 
    Current portion of operating lease liabilities1,050  1,005 
    Accrued expenses and other current liabilities12,682  17,918 
    Total current liabilities18,718  24,373 
    Operating lease liabilities, net of current portion13,154  13,439 
    Total liabilities31,872  37,812 
    STOCKHOLDERS' EQUITY:   
    Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding—  — 
    Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 36,067,786 and 31,841,084 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively3  3 
    Additional paid-in capital878,484  713,636 
    Accumulated deficit(424,540) (381,426)
    Total stockholders' equity453,947  332,213 
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY485,819  370,025 



    Primary Logo

    Get the next $KROS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    12/12/2024Outperform → Mkt Perform
    William Blair
    12/12/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

      Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced topline data from the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arte

      5/29/25 6:55:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees

      Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1's Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Urges Stockholders to Protect the Value of Their Investment by Voting "FOR" All Three of the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling o

      5/27/25 1:45:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

      ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas, May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that Keros stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 4, 2025.

      5/21/25 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Adar1 Capital Management, Llc claimed ownership of 4,456,706 shares (SEC Form 3)

      3 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 8:58:32 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Seehra Jasbir exercised 49,367 shares at a strike of $0.30, increasing direct ownership by 20% to 302,223 units (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/7/25 4:15:07 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $KROS
    Financials

    Live finance-specific insights

    See more
    • Keros Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

      1/21/25 7:51:46 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00

      1/17/25 11:09:49 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Keros Therapeutics with a new price target

      Oppenheimer reiterated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $63.00 from $102.00 previously

      12/16/24 8:15:23 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

      LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2025. "In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim

      5/6/25 4:01:42 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Review of Strategic Alternatives

      Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors (the "Board") has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, th

      4/10/25 6:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

      Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy ("DMD") and other neuromuscular indicationsKeros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interactionKeros to host a conference call and webcast today, March 31, 2025, at 8:00 a.m. ET LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic

      3/31/25 6:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      2/13/24 6:38:35 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      2/9/24 9:16:07 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      1/26/24 5:26:51 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    SEC Filings

    See more
    • Keros Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

      8-K - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/29/25 6:58:59 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Keros Therapeutics Inc.

      DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/27/25 1:49:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Keros Therapeutics Inc.

      DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/19/25 8:02:47 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Leadership Updates

    Live Leadership Updates

    See more
    • Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

      LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

      10/16/24 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

      LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply

      5/28/24 4:01:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

      LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a

      4/19/23 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care